Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.

This review discusses the psychological impact of alopecia on women and reports no new clinical findings, highlighting the effect on self-esteem and quality of life.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

This review discusses various substances that can impact male fertility and stresses that products should be confirmed 'sperm-safe' through rigorous testing, not assumptions; it reports no new study results.

This review discusses recent data on the use of anabolic-androgenic steroids and other steroid compounds and reports no new clinical results.

This review examines androgen replacement therapy in women for treating androgen deficiency symptoms and reports no new clinical results, while noting potential safety within a specific dose range.

This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

In this study, the authors concluded that COVID-19 may not cause direct long-term harm to testicular function, but temporary indirect effects could occur, suggesting a possible delay in pursuing parenthood post-recovery.

Randomized trials reported that testosterone therapy improved sexual function in postmenopausal women with hypoactive sexual desire disorder, particularly those who had undergone oophorectomy, with reversible and well-tolerated side effects.

This review discusses various skin lesions associated with endocrinologic disorders such as Cushing's syndrome and adrenal insufficiency, and it reports no new clinical results.

This review discusses the physiopathology of androgenetic alopecia and evaluates various traditional and emerging treatments, reporting no new clinical results but highlighting the need for enhanced treatment strategies.

This article reviews the use of cross-sex hormonal therapy in transmen and reports that it is reasonably safe, suggesting monitoring should be frequent initially but can be less frequent over time.

In this study, treatment with 1 mg of finasteride was associated with stable sexual function, suggesting that sexual side effects may be less common than indicated in clinical trials.

This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.

This study found that finasteride significantly reduced hirsutism in women with idiopathic hirsutism or polycystic ovary syndrome over six months, suggesting its potential effectiveness for this condition.

This review suggests that most mutations in the SRD5A2 gene show no clear genotype-phenotype correlation in 5-α-Reductase deficiency, although mutation location affects severity.

This article examines the evidence regarding finasteride's sexual side effects and offers recommendations for patient counseling but reports no new clinical findings.

This review discusses the clinical use of anti-androgen medications and highlights emerging evidence supporting plant-derived anti-androgens like spearmint tea for managing PCOS, but reports no new clinical results.

This study found that intravaginal testosterone significantly improved sexual satisfaction and reduced dyspareunia in postmenopausal women using aromatase inhibitors, with no effect on urinary incontinence.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This review discusses hormone-modulating therapies for androgen-mediated cutaneous disorders in women but reports no new clinical results and highlights the need for more rigorous studies.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

This review discusses the potential persistent adverse effects associated with 5α reductase inhibitor treatment for androgenetic alopecia but provides no new clinical results; it emphasizes the importance of discussing these risks with patients.

This article states that hormone therapy with estrogens and antiandrogens for transgender females is within an obstetrician-gynecologist's practice scope and involves careful dosing and monitoring to manage short-term thrombotic risks.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.